A prospective observational study investigating clinicopathological and molecular biological features in FGFR2-fusion positive biliary tract cancer

A prospective observational study investigating clinicopathological and molecular biological features in FGFR2-fusion positive biliary tract cancer - Prelude trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014767

Enrollment

500

Registered

2014-08-05

Start date

2014-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bilary tract cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Diagnosed as intrahepatic bile duct cancer or perihilar bile duct cancer 2) Chemotherapy is underway or preparing for unresectable or recurrent cancer 3) Specimens for genetic analysis are available 4) Written informed consent

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Frequency of FGFR-fusion gene positive patients in intrahepatic biliary tract cancer	—

Countries

Japan

Contacts

Public ContactChigusa Morizane

National Cancer Center, Tokyo Hepatobiliary and Pancreatic Medical Oncology

cmorizan@ncc.go.jp03-3542-2511

Outcome results